Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency.
about
Transfusion medicine service policies for recombinant factor VIIa administration.Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.Factor VII Deficiency.Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product.Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trialPrevention of intraventricular haemorrhage: a role for recombinant activated factor VII?Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature.Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.Efficacy of NovoSeven during surgery on a haemophiliac with previous history of inhibitors.A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.Spontaneous umbilical cord haematoma and congenital factor VII deficiency.Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants.Severe FVII deficiency caused by a new point mutation combined with a previously undetected gene deletion
P2860
Q33362187-2C654431-42DE-48A4-85A1-1FDB5FBD6F91Q33366023-87A3B022-DEBA-4FAE-BF40-504E78D4B7EDQ34786241-241A0637-468C-4DEE-A57B-7D4B4555F311Q35126229-132FFFD4-1F9B-4D03-A4ED-979A2725271EQ35879063-C8C5F440-7EA5-4D09-ABBE-BBF81A06A061Q35882779-3EB7CA60-35B5-4441-B93F-47E2FF26AF89Q36366931-EEF24946-745C-4348-BD26-1F48EB51B280Q36392691-AE58E734-625A-4015-9AD5-A60F783DD6CDQ36493713-B189ED2E-EC8F-4708-B997-E7EDE4F5F95AQ36570888-6AB7497D-0EA7-486D-B613-EEFB42F05683Q36635051-2B203F17-B289-4357-9EC6-DC8714AB7F5CQ36987270-2B53D6D6-FF77-461D-B1BF-1F720BC61E42Q45858257-ECC47BFF-8119-45AB-93DB-21649A5DD2D7Q45863434-FF9254EE-6207-4617-A562-538F15929201Q45873746-E24E26C9-6F36-4A3C-8744-CD88345C86A5Q45874642-CCE1491D-E432-4372-A202-30A9B64A8F5FQ47174603-9BCDB9F5-7C2D-4903-953F-8B638ED314F7Q57730202-EBC7CBEB-7C54-469A-A4F4-20E826395843
P2860
Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Clinical efficacy and recovery ...... vere neonatal FVII deficiency.
@en
type
label
Clinical efficacy and recovery ...... vere neonatal FVII deficiency.
@en
prefLabel
Clinical efficacy and recovery ...... vere neonatal FVII deficiency.
@en
P2093
P2860
P1433
P1476
Clinical efficacy and recovery ...... vere neonatal FVII deficiency.
@en
P2093
P2860
P356
10.1046/J.1365-2516.2000.00345.X
P577
2000-01-01T00:00:00Z